SCHEMBL3978051

SCHEMBL3978051

CCCCCCn1c(=O)[nH]c(=O)c2[nH]c(C(Cc3ccccc3F)c3ccc(NC(C)=O)cc3)nc21

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PCK1 P35558 4/20 0.50
ADORA2B P29275 3/20 0.39
ADORA2A P29274 2/20 0.39
KDM4E B2RXH2 3/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
ALDH1A1 P00352 3/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
RGS12 O14924 1/20 0.38
LMNA P02545 1/20 0.38
POLB P06746 2/20 0.37
MAPT P10636 1/20 0.37
PARP1 P09874 1/20 0.37
NPSR1 Q6W5P4 1/20 0.36
HSD17B10 Q99714 1/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3976949 0.97 PCK1 (0.53) PCK1ADORA2BADORA2AKDM4EMEN1
SCHEMBL3985140 0.94 PCK1 (0.47) PCK1ADORA2BADORA2A
SCHEMBL3987439 0.93 PCK1 (0.45) PCK1ADORA2BADORA2AKDM4EMEN1
SCHEMBL3976936 0.90 PCK1 (0.45) PCK1ADORA2BADORA2AKDM4EMEN1
SCHEMBL3985334 0.89 PCK1 (0.42) PCK1ADORA2BADORA2AMEN1KMT2A
SCHEMBL4261473 0.89 PCK1 (0.43) PCK1ADORA2BADORA2AKDM4EMEN1
SCHEMBL4092481 0.89 PCK1 (0.55) PCK1ADORA2BADORA2AKDM4EMEN1
SCHEMBL4285441 0.88 PCK1 (0.42) PCK1ADORA2BADORA2AMEN1KMT2A
SCHEMBL3980810 0.88 PCK1 (0.46) PCK1ADORA2BADORA2AKDM4EMEN1
SCHEMBL3981236 0.88 PCK1 (0.45) PCK1ADORA2BADORA2AKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7135475-B2 Antidiabetic agents HOFFMANN-LA ROCHE INC. (US) 2006-11-14 US claimed
US-20040014766-A1 Amide substituted xanthine derivatives HOFFMANN-LA ROCHE INC. 2004-01-22 US claimed
EP-1515972-B1 AMIDE SUBSTITUTED XANTHINE DERIVATIVES WITH GLUCONEOGENESIS MODULATING ACTIVITY HOFFMANN LA ROCHE (CH) 2009-05-13 EP disclosed
US-7135475-B2 Antidiabetic agents HOFFMANN-LA ROCHE INC. (US) 2006-11-14 US disclosed
EP-1515972-A1 AMIDE SUBSTITUTED XANTHINE DERIVATIVES WITH GLUCONEOGENESIS MODULATING ACTIVITY F. HOFFMANN-LA ROCHE AG (CH) 2005-03-23 EP disclosed
US-20040014766-A1 Amide substituted xanthine derivatives HOFFMANN-LA ROCHE INC. 2004-01-22 US disclosed
WO-2003106459-A1 AMIDE SUBSTITUTED XANTHINE DERIVATIVES WITH GLUCONEOGENESIS MODULATING ACTIVITY F. HOFFMANN-LA ROCHE AG (CH) 2003-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014766-A1 Amide substituted xanthine derivatives GYS2, GLS2, PYGL PCK1 14/4885ADORA2B 931/4885ADORA2A 403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.